TARGETED THERAPY FOR
LUNG CANCER (EGFR, ALK)
For EGFR-mutant and ALK-rearranged NSCLC, targeted therapy is not just one option -- it is the treatment with the strongest clinical rationale and the most compelling outcome data. Molecular testing before any treatment starts is non-negotiable.
Key Numbers for EGFR and ALK Targeted Therapy
- 18-20 moMedian PFS: osimertinib first-line (EGFR-mutant NSCLC)
- >4 yearsMedian PFS: lorlatinib first-line (ALK-rearranged NSCLC)
- 7-14 daysComprehensive NGS panel turnaround time
- 80%+Objective response rate: osimertinib first-line
Approved Targeted Options in NSCLC
| Mutation | Preferred Agent | Notes |
|---|---|---|
| EGFR exon 19 del / L858R | Osimertinib (Tagrisso) | Third-generation; preferred over erlotinib/gefitinib; CNS active; adjuvant approved post-resection |
| ALK rearrangement | Lorlatinib or alectinib | Lorlatinib covers most resistance mutations; alectinib strong CNS activity; both preferred over crizotinib |
| ROS1 rearrangement | Entrectinib or crizotinib | Entrectinib preferred for CNS activity |
| KRAS G12C | Sotorasib or adagrasib | First approved drugs for previously undruggable KRAS mutation |
| RET fusion | Selpercatinib or pralsetinib | Highly selective RET inhibitors; strong CNS activity |
| MET exon 14 skipping | Capmatinib or tepotinib | MET-selective inhibitors; approved for this specific alteration |
Frequently Asked Questions
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Questions About Targeted Therapy for Your Lung Cancer?
CancerFax reviews your NGS molecular report and connects you with specialist lung oncologists experienced in EGFR and ALK-targeted treatment.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.